
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences is poised for significant market growth in the cancer screening sector due to an under-screened patient population and expansion into the 45-49 age demographic, leading to increased revenue and repeat orders. The launch of Cologuard Plus, which offers heightened accuracy and higher Medicare pricing, alongside a robust sales organization, positions Exact Sciences favorably to achieve or surpass near-term financial targets. Furthermore, the company continues to benefit from a strong portfolio of best-in-class diagnostic products and possesses ample room for growth, supported by industry-leading margins and profitability in the near to medium term.
Bears say
Exact Sciences has demonstrated mixed financial performance, finishing fiscal year 2024 with results slightly below initial guidance despite a positive surprise in 4Q revenue. The company faces potential regulatory surprises that could adversely affect revenue while also inflating operational costs, raising concerns about compliance risks. Furthermore, the overall downward trend in reimbursement for cancer screening could pose long-term challenges, creating uncertainty around the company’s future revenue sustainability.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares